A Harvard‑led analysis published in JAMA Internal Medicine found NIH funding cuts from late February to mid‑August led to termination of 383 trials, affecting more than 74,000 enrolled participants. The cancelled programs spanned cancer, infectious disease, reproductive health and mental health studies, with 43 trials classified as active and delivering interventions when grants were stopped. Researchers reported disruptions including trials that never started, halted interventions, loss of monitoring, and unpublished results; ethicists and academic leaders called the impact "profound and substantial." The data raise questions about governance, participant protection and contingency planning when centralized funding shifts abruptly. The findings prompted scrutiny of NIH policy decisions, potential institutional responses to preserve participant safety, and debates in Washington over research prioritization and the downstream effect on translational pipelines.